Prevention of radial artery occlusion with rivaroxaban after transradial coronary procedures: The RIVARAD multicentric randomized trial

Reported from TCT 2022

Aaysha Cader interviews Rania Hammami, Principal Investigator of the RIVARAD trial. They discuss the design and results of the trial which was presented during #TCT2022.

RIVARAD is the first multicentric randomized trial with 30-day RAOs as the primary endpoint, which proved the efficacy of short-term use of rivaroxaban in preventing RAO in real-world daily practice using the radial approach.